Aprea Therapeutics, Inc.

Aprea Therapeutics Announces Third Quarter 2026 Financial Results

Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026)…